Piper Jaffray analyst Christopher Raymond reiterated an Overweight rating and $60.00 price target on Aimmune Therapeutics (NASDAQ: AIMT) after hosting ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE